Skip to main content

Vertex Pharmaceutic(VRTX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low488.79
Day High499.49
Open:497.88
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

TOP STORIES: Vertex Pharmaceutic

Select a category then submit the form to load news
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Design Therapeutics (DSGN) and Vertex Pharmaceuticals (VRTX)
Tipranks
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Cartesian Therapeutics (RNAC) and Vertex Pharmaceuticals (VRTX)
StockStory
Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc
LASR
Tipranks
UBS Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)
Tipranks
Scotiabank Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Tipranks
Analysts Are Bullish on These Healthcare Stocks: Atai Beckley N.V. (ATAI), BridgeBio Oncology Therapeutics (BBOT)
Tipranks
Wall Street Analysts Are Neutral on Top Healthcare Picks
Tipranks
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and HCA Healthcare (HCA)
StockStory
Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today
VRTX
Motley Fool
Buying This 1 Biotech Stock Now Could Help Make You a Multimillionaire Retiree
Tipranks
BMO Capital Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)
Tipranks
Vertex says JOURNAVX demonstrates ‘effective’ pain management in study
Motley Fool
2 Biotech Giants to Buy in 2026
Motley Fool
Forget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams Of
Motley Fool
Is CRISPR Therapeutics Stock Too Risky to Buy Right Now?
Tipranks
Vertex Expands VX-548 Safety Profile With New Breastfeeding Study
Motley Fool
2 Top Healthcare Stocks to Buy in February
Motley Fool
Forget Centessa Pharmaceuticals: This Rare‑Disease Specialist Has a Superior Portfolio and Pipeline
StockStory
2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question
NFLX
Motley Fool
The Ultimate Biotech Stock to Buy With $500 Right Now
Motley Fool
Could Vertex Stock Help Turn $100,000 Into $1 Million by 2036?
Motley Fool
The Gene‑Therapy Breakthrough Story You'll Be Mad You Ignored at These Prices
Tipranks
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Insulet (PODD)
MarketBeat
CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows
MarketBeat.com
Tipranks
Analysts Conflicted on These Healthcare Names: Baxter International (BAX), Labcorp Holdings (LH) and Vertex Pharmaceuticals (VRTX)
StockStory
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q4 Earnings Call
VRTX
StockStory
1 S&P 500 Stock with Competitive Advantages and 2 We Turn Down
VMC
Tipranks
Analysts Conflicted on These Healthcare Names: Biodesix (BDSX), Ocular Therapeutix (OCUL) and Vertex Pharmaceuticals (VRTX)
Tipranks
Vertex Pharmaceuticals (VRTX) Gets a Buy from Barclays
Motley Fool
Vertex: The Quiet Biotech Compounder I'd Happily Hold Through Any Market Crash
Tipranks
Analysts Offer Insights on Healthcare Companies: Actinogen Medical (OtherATGGF) and Vertex Pharmaceuticals (VRTX)
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX) and 10x Genomics (TXG)

Profile

Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which are collectively approved to treat the people with CF in North America, Europe and Australia. Trikafta, Vertex's triple combination regimen, was approved by the FDA for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency and muscular dystrophies. Pimodivir/VX-787, for the treatment of influenza, was out-licensed to Janssen while oncology candidates VX-970, VX-984 and VX-803 were divested to Merck KGaA.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.